Opinion|Videos|May 3, 2024
MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.
Advertisement
Episodes in this series
Advertisement
Related to this article
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Investigators are evaluating cesalatamig among patients with advanced cancer in the international phase 1/2 BiPAVE-001 trial.
The FDA granted fast track designation to the oral pan-KRAS inhibitor KST-6051 for patients with KRAS-mutant advanced or metastatic solid tumors.
Based on updated data from the TRUST-1 trial, a sNDA for taletrectinib has been approved by the FDA for patients with TKI-naive ROS1+ NSCLC.
Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5